More about

Empagliflozin

News
August 18, 2021
1 min read
Save

FDA approves empagliflozin for treatment of HFrEF in patients with or without diabetes

FDA approves empagliflozin for treatment of HFrEF in patients with or without diabetes

Boehringer Ingelheim and Eli Lilly announced the FDA has approved empagliflozin to reduce risk for CV death and HF hospitalization in adults with HF with reduced ejection fraction regardless of whether they have diabetes.

View more